From Barchart: 2024-11-15 07:37:00

Guggenheim analysts reiterated a Buy rating and $23 price target for Cabaletta Bio (NASDAQ:CABA) after positive third-quarter results, citing growth prospects. Enrollment in clinical trials has accelerated to 16 patients at 40 sites from 9 patients in August 2024. The company plans to discuss a registrational pathway with the FDA for lead candidate CABA-201 in 2025.

Cabaletta presented data at the ACR meeting on eight patients with conditions like Myositis, SLE, and SSc. Initial data from the gMG study is expected in the first half of 2025, expanding its pipeline. These developments mark significant progress for the company’s programs and demonstrate its commitment to advancing treatment options.



Read more at Barchart:: Guggenheim Reiterates Buy Rating on Cabaletta Bio …